Skip to content

Effects of Qiangji Baduanjin on Daily Living Ability and Quality of Life in RA Patients with Sarcopenia

Effects of Qiangji Baduanjin on Daily Living Ability and Quality of Life in RA Patients with Sarcopenia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001102
Enrollment
Unknown
Registered
2026-04-28
Start date
2024-06-24
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

Control Group:Continue the basic drug treatment plan and inform the patient about the standard care practices for the disease.
Experimental Group:Continue the basic drug treatment plan and inform the patient about the standard care practices for the disease, and implement Qiangji Baduanjin intervention.

Sponsors

Dongfang Hospital, Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) Aged 18 to 75 years; 2) Meeting the 2010 ACR/EULAR classification criteria for rheumatoid arthritis and the 2019 AWGS diagnostic criteria for sarcopenia; 3) DAS28 score < 5.1; 4) Not participating in regular physical exercise during leisure time; 5) Patient and family members consent and sign the informed consent form;

Exclusion criteria

Exclusion criteria: 1) Concurrent conditions including ankylosing spondylitis, systemic lupus erythematosus, gout, Sjögren's syndrome, and other rheumatic and immunological disorders; 2) Concurrent severe primary diseases affecting the cardiovascular, hepatic, renal, endocrine, or haematopoietic systems, or psychiatric disorders; 3) Concurrent severe RA complications such as secondary severe infections, vasculitis, and other acute or chronic infections; 4) Muscle atrophy resulting from primary muscular disorders (e.g., myasthenia gravis, muscular dystrophy), chronic debilitating conditions (e.g., malignant tumours), trauma, or other causes; 5) Inability to complete the trial due to severe disability, loss of self-care capacity, cognitive impairment, or similar factors.

Design outcomes

Primary

MeasureTime frame
Health Lifestyle Questionnaire - Disability Index;

Secondary

MeasureTime frame
morning stiffness duration;Tender joint count;Swollen joint count;Visual Analog Scale (VAS);Disease Activity Score;Simplified Disease Activity Index;Clinical Disease Activity Index;TCM Syndrome Score;Grip strength;Body composition;6-Meter Gait Speed Test;Timed Up and Go Test;Anxiety Self-Rating Scale;Depression Self-Rating Scale;

Countries

China

Contacts

Public ContactYingzi Li

Beijing University of Chinese Medicine

liyingzi00@163.com18511989578

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 11, 2026